论文部分内容阅读
Ly146032是一种新型的环状脂肽类抗生素,它是由含相同肽核的酸性抗生素复合物A219786衍生的。已证明:Ly146032对所有实验过的链球菌和葡萄球菌,包括肠球菌有很强的杀菌作用。Ly146032对肠球菌活性比万古霉素更强,而一般肠球菌的大多数菌株对万古霉素耐药。因而有可能单用Ly146032治疗严重的肠球菌感染。目前,系统肠球菌感染通常是用青霉素或氨苄青霉素与氨基糖苷类抗生素如庆大霉素联用来治疗。对青霉素过敏的病人,或者因某种原因无法接受该药治疗的病人,则改用万古霉素加一种氨基糖苷类抗生素治疗。显然大多数临床医生会担心这两种药物联用的潜在耳、肾毒性。已建立的肠球菌性肾盂肾炎大鼠模型作
Ly146032 is a novel cyclic lipopeptide antibiotic that is derived from the acidic antibiotic complex A219786 containing the same peptide nucleus. It has been demonstrated that Ly146032 has a strong bactericidal effect on all tested streptococci and staphylococci, including enterococci. Ly146032 is more active against enterococci than vancomycin, whereas most strains of enterococci are resistant to vancomycin. It is therefore possible to treat only a serious enterococcal infection with Ly146032. Currently, systemic enterococcal infections are usually treated with penicillin or ampicillin in combination with aminoglycoside antibiotics such as gentamicin. Patients allergic to penicillin, or for some reason can not receive the drug treatment of patients treated with vancomycin plus an aminoglycoside antibiotic treatment. It is clear that most clinicians are concerned about the potential ototoxicity of the two drugs in combination. Established enterococcal pyelonephritis rat model